You are viewing the site in preview mode
Skip to main content
|
Variables
|
Total
|
Event-free group (n = 21)
|
Adverse cardiac event group (n = 20)
|
p-value
|
|---|
|
Clinical characteristics
|
|
Age, years
|
47.0 ± 11.64
|
48.8 ± 10.0
|
45.2 ± 13.2
|
0.32
|
|
Male gender, n (%)
|
33 (80)
|
18 (86)
|
15 (75)
|
0.42
|
|
NYHA III-IV class, n (%)
|
36 (88)
|
17 (81)
|
19 (95)
|
0.34
|
|
Systolic BP, mm Hg
|
114 (104, 130)
|
120 (110, 130)
|
110 (103, 120)
|
0.09
|
|
Diastolic BP, mm Hg
|
80 (70, 80)
|
80 (70, 80)
|
73 (69, 80)
|
0.21
|
|
Concomitant cardiac medication/
|
|
ACE-I/ARB, n (%)
|
31 (76)
|
17 (81)
|
14 (70)
|
0.48
|
|
Beta-blocker, n (%)
|
39 (95)
|
20 (95)
|
19 (95)
|
1
|
|
MRA, n (%)
|
37 (90)
|
19 (95)
|
18 (86)
|
0.6
|
|
Loop diuretics, n (%)
|
38 (93)
|
19 (91)
|
19 (95)
|
1
|
|
Biomarkers
|
|
eGFR, ml/min/1.73 m2
|
83 (71, 102)
|
83 (73, 100)
|
86 (71, 103)
|
0.82
|
|
BNP, ng/l
|
809 (79, 1523)
|
300 (47, 851)
|
1294 (506. 2920)
|
< 0.01
|
|
Troponin T, pg/ml
|
29.1 (17.3, 46.5)
|
23.6 (9.4, 41.7)
|
33 (25.2, 65.2)
|
0.09
|
|
Hemodynamic measurements
|
|
mPAP, mmHg
|
28 (21, 38)
|
23 (21, 34)
|
33 (27, 40)
|
0.09
|
|
Elevated mPAP (> 20 mmHg), n (%)
|
33 (80)
|
17 (81)
|
16 (80)
|
1
|
|
PCWP, mmHg
|
19 (15, 27)
|
17 (14, 22)
|
22 (16, 33)
|
0.18
|
|
Elevated PCWP (> 15 mmHg), n (%)
|
27 (66)
|
12 (57)
|
15 (75)
|
0.23
|
|
PVR, Wood units
|
1.9 (1.2, 3.1)
|
1.6 (1, 2.4)
|
2.5 (1.8, 3.5)
|
< 0.05
|
|
Elevated PVR (≥ 3 Wood units), n (%)
|
10 (25)
|
3 (15)
|
7 (35)
|
0.14
|
|
Cardiac index, l/min/m2
|
2.3 ± 0.7
|
2.4 ± 0.6
|
2.2 ± 0.8
|
0.49
|
- Values are expressed as: mean ± SD, median (25th percentile, 75th percentile) or n (%)
- ACE-I Angiotensin-converting enzyme inhibitor, ARB Angiotensin II receptor blocker, BNP B type natriuretic peptide, BP Blood pressure, eGFR Estimated glomerular filtration rate, mPAP mean pulmonary arterial pressure, MRA Mineralocorticoid receptor antagonist, NYHA New York Heart Association, PCWP pulmonary capillary wedge pressure, PVR pulmonary vascular resistance
